EN DE
Watch Lotus Eye Hospital and Institute Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lotus Eye Hospital and Institute Limited (LOTUSEYE) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Lotus Eye Hospital and Institute Limited stock ₹80.10, price ₹101, that is 20.8% below the price, quality 48 out of 100. Rating: overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE947I01017

LE Lotus Eye Hospital and Institute Limited logo Some data Nov 15, 2026

Lotus Eye Hospital and Institute Limited

LOTUSEYE · NSE

Expensive (fair value 21% below the price) and price moving sideways, but company just good enough: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +26% vs. a year ago. 
Quality 48/100 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +10.7 %/yr in INR) 
Thin margins · 0.3% net margin (TTM) 
Some data 
Fair value ₹80.10 · Overvalued 
Negative free cash flow 
Trails peers (2/11) 
Narrow moat 20/100 · thin data
⚠ Small free float
Watch Lotus Eye Hospital and Institute Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹141.38 ₹39.62 Fair Value ₹80.10 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range ₹39.62 – ₹141.38 · fair‑value band ₹60.31 – ₹99.89 · the ₹101.19 price screens above the ₹80.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Lotus Eye Hospital and Institute in your weekly email

Every Wednesday you see whether Lotus Eye Hospital and Institute is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India.

Show moreShow less

The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments.

It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses.

The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.

Stock analysis

Lotus Eye Hospital and Institute Limited (LOTUSEYE) currently trades at ₹101.19, while our model-based Fair Value estimate is ₹80.10, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹71.62 per share, and 4 of the 12 models we run sit above the ₹101.19 price.

Bear case: the Earnings-Based group reads lowest at ₹31.10, and 8 of the 12 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹60.31 (bear) to ₹99.89 (bull), the price of ₹101.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Lotus Eye Hospital and Institute Limited reported revenue of ₹537M in FY2026 versus ₹389M in FY2022, a compound +8.4%/yr. Reported net income was ₹804K in FY2026, compounding −59.5%/yr from FY2022.

Key figures

Market cap ₹2.1B (≈ $22.2M) Micro · P/S ratio 3.98 · EPS (TTM) ₹0.0800 · Net margin 0.3% · Return on equity 0.1% · Return on assets (EBIT) 5.7% (5-year average) · Operating margin 7.7% · Revenue (TTM) ₹573M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −21%, LOTUSEYE screens richer than that median.

Fair Value models

Bear ₹60.31 Fair Value ₹80.10 Bull ₹99.89
Price ₹101.19 · Downside -20.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹0.0504 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹1,393 ₹1,503 ₹1,707 76
Gordon GGM ₹3.77 ₹7.54 ₹10.37 67
Growth-Adj P/E ₹49.94 ₹71.62 ₹92.35 67
All 12 models by family
Earnings-Based
Graham-Dodd ₹24.50 ₹79.16 ₹105.54 64
Lynch FV ₹21.67 ₹31.10 ₹40.52 61
PEG = 1.0 ₹21.67 ₹31.10 ₹40.52 57
Dividend Discount
Gordon GGM ₹3.77 ₹7.54 ₹10.37 67
DDM Multi-Stage ₹3.77 ₹6.60 ₹8.48 66
Multiples
P/E Multiple ₹60.31 ₹80.10 ₹99.89 63
P/S Multiple ₹46.18 ₹62.20 ₹77.27 58
P/B Multiple ₹3,646 ₹4,862 ₹6,077 55
EV/EBITDA ₹1,066 ₹1,602 ₹2,138 66
Asset-Based
NCAV (Graham) ₹1,357 ₹1,819 ₹2,715 54
Economic Profit
Residual Income ₹1,393 ₹1,503 ₹1,707 76
Growth Earnings
Growth-Adj P/E ₹49.94 ₹71.62 ₹92.35 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 49
Does it invest with discipline instead of growing at any price?
Low Volatility 65
How calm the share price moves, does not count
Price momentum 33
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Start year 2021 (pandemic). Over 10 years: +5.6% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−44.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−44.4% vs −11.1%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → −1%
Pace: the 5-year rate starts in 2021 (pandemic)

LOTUSEYE screens overvalued: fair value 21% below the price. Compare with HCA Healthcare, Inc →

Compare Lotus Eye Hospital and Institute Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside −22.3% · Below median
Profitability
Return on equity (12 months) 0.1% · Bottom 25%
Return on assets 0.1% · Bottom 25%
Net margin (12 months) 0.3% · Bottom 25%
Operating margin (12 months) 7.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 26.2% · Top 25%
Balance sheet
Debt / equity 0.17× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 3.55× · Pricier than median
P/S (12 months) 3.73× · Priciest 25%
EV/EBITDA 49.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 33
FUTURE (revenue growth)100 · sector 33
PAST (return on equity)1 · sector 32
HEALTH (low debt)92 · sector 90
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lotus Eye Hospital and Institute Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lotus Eye Hospital and Institute Limited Fair Value". https://www.fairvalue-calculator.com/stock/LOTUSEYE

Frequently asked questions

Is Lotus Eye Hospital and Institute Limited (LOTUSEYE) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ₹80.10 versus a price of ₹101.19, about 21% lower (overvalued).
What is the fair value of LOTUSEYE?
Our model-based fair value for Lotus Eye Hospital and Institute Limited is ₹80.10 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹101.19.
What is the quality score of LOTUSEYE?
Lotus Eye Hospital and Institute Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
Our model-based price target is the fair value of ₹80.10 (as of Nov 15, 2026) from 12 valuation models. Cautious scenario ₹60.31, optimistic scenario ₹99.89. It is a calculation from audited fundamentals, not an analyst target.
What is the Lotus Eye Hospital and Institute Limited stock forecast for 2026?
Our models put fair value at ₹80.10, about 21% lower versus a price of ₹101.19 (overvalued). Cautious scenario ₹60.31, optimistic scenario ₹99.89. The calculation is refreshed regularly with new filings.
What is the revenue of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
Lotus Eye Hospital and Institute Limited reported trailing-twelve-month revenue of about ₹573M (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lotus Eye Hospital and Institute Limited it is ₹80.10 per share (as of Nov 15, 2026), against a price of ₹101.19. It is the blended result of 12 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Lotus Eye Hospital and Institute Limited stock overvalued or undervalued in 2026?
As of Nov 15, 2026, LOTUSEYE trades above its calculated fair value: price ₹101.19, fair value ₹80.10, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LOTUSEYE?
No. The price is what the market pays today (₹101.19); the fair value is what the company's own numbers justify (₹80.10). For Lotus Eye Hospital and Institute Limited the two are ₹21.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lotus Eye Hospital and Institute Limited worth?
The market values Lotus Eye Hospital and Institute Limited at about ₹2.1B (market capitalisation, as of Nov 15, 2026). Per share that is ₹101.19; our models calculate a fair value of ₹80.10 per share.
What do the bullish and bearish scenarios say about LOTUSEYE?
Our models span a range for Lotus Eye Hospital and Institute Limited: cautious scenario ₹60.31, base ₹80.10, optimistic ₹99.89 per share (as of Nov 15, 2026, price ₹101.19). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
Balance-sheet figures for Lotus Eye Hospital and Institute Limited (as of Nov 15, 2026): return on equity 0.1%, debt of 0.17 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is LOTUSEYE from its 52-week high?
Lotus Eye Hospital and Institute Limited trades at ₹101.19, about 28% below its 52-week high of ₹141.38 and 3% above the low of ₹98.22 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹80.10 is for.
Which stocks are comparable to Lotus Eye Hospital and Institute Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lotus Eye Hospital and Institute Limited stock attractive at the current price?
The data as of Nov 15, 2026: price ₹101.19, calculated fair value ₹80.10 (−21%), Quality Score 48/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LOTUSEYE calculated?
We run Lotus Eye Hospital and Institute Limited through 12 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹80.10 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Lotus Eye Hospital and Institute Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
The closing price on Nov 16, 2026 was ₹101.19. Our model-based fair value is ₹80.10, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lotus Eye Hospital and Institute Limited right now?
Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The price sits above our optimistic bull case: the favourable scenario is already priced in. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Lotus Eye Hospital and Institute Limited

How large is the market capitalisation of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
The market capitalisation of Lotus Eye Hospital and Institute Limited is ₹2.1B (≈ $22.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
The price-to-sales ratio of Lotus Eye Hospital and Institute Limited is 3.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
Earnings per share at Lotus Eye Hospital and Institute Limited are ₹0.0800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
The net margin of Lotus Eye Hospital and Institute Limited is 0.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
The return on equity (ROE) of Lotus Eye Hospital and Institute Limited is 0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
On an EBIT basis the return on assets of Lotus Eye Hospital and Institute Limited is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
The operating margin of Lotus Eye Hospital and Institute Limited is 7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
Revenue at Lotus Eye Hospital and Institute Limited is growing 26.2% versus a year earlier (3y avg +4.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
Earnings per share at Lotus Eye Hospital and Institute Limited are growing 15.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lotus Eye Hospital and Institute Limited (LOTUSEYE) generate?
The free cash flow of Lotus Eye Hospital and Institute Limited is −₹106M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lotus Eye Hospital and Institute Limited (LOTUSEYE) carry?
The net debt of Lotus Eye Hospital and Institute Limited is ₹120M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lotus Eye Hospital and Institute Limited in the live analysis

One click puts Lotus Eye Hospital and Institute Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.